Atossa Therapeutics (ATOS) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Press Release: Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
Dow JonesFeb 5 08:00 ET
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care
Atossa TherapeuticsFeb 5 00:00 ET
Atossa Therapeutics: Strong Strategic Positioning and Patent Resilience Justifies Buy Rating
TipRanksJan 30 11:25 ET · Ratings
Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen
MT NewswiresJan 30 09:38 ET
Express News | Atossa Therapeutics - Decision Has No Impact on Formulations Currently in Clinical Development
ReutersJan 30 08:17 ET
Express News | Atossa Therapeutics - Will Not Be Pursuing an Appeal From Ptab Decision
ReutersJan 30 08:17 ET

Comments

73844802

Feb 7 10:59

Watch SOUN’s Growth Potential

The breakout for $SoundHound AI (SOUN.US)$ could be imminent. As $Bionano Genomics (BNGO.US)$ moves up in genomics and $Atossa Therapeutics (ATOS.US)$ focuses on therapies, this is one week to keep an eye on!
YouTube

1

Jaguar8

Jan 30 07:18

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
Thursday, 30th January at 8:17 am
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Boar...

1

Jaguar8

Dec 12, 2024 07:17

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Atossa Therapeutics (NASDAQ: ATOS)has announced groundbreaking research findings on compounds that work synergistically with (Z)-endoxifen for breast cancer treatment. The discovery, presented at the 2024 San Antonio Breast Cancer Symposium, utilized both insilico and chemic...

Jaguar8

Dec 11, 2024 07:18

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Wednesday, 11th December at 8:15 am
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer
Data to be Presented in a Poster Spotlight Session During the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 11, 202...

Jaguar8

Dec 10, 2024 08:05

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
Tuesday, 10th December at 9:05 am
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today ann...

1

ATOS Atossa Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks